Recognizing the Overlooked: A Pharmacist's Guide to Early Detection and Diagnostic Optimization in Transthyretin Amyloidosis Cardiomyopathy

This activity was originally presented at the 2026 Cardiology Day of Education.

Endorsed by the American College of Cardiology

Disclaimer: ACCF makes no guarantees or promises regarding the contents of PTCE’s program.

Program Information

Transthyretin amyloidosis cardiomyopathy (ATTR-CM) carries a substantial and historically underestimated clinical burden, especially among patients with heart failure with preserved ejection fraction (HFpEF). Due to its overlapping presentation with HFpEF and other cardiovascular conditions, ATTR-CM remains frequently underrecognized and undiagnosed. Compounding this challenge is that patients with ATTR-CM may have suboptimal responses to standard heart failure therapies, which can serve as an important clinical clue warranting further evaluation. Early detection of ATTR-CM is paramount, as disease-modifying therapies (DMTs) demonstrate the greatest benefit when initiated in earlier stages. Although the American College of Cardiology released a Concise Clinical Guidance report on the evaluation and management of ATTR-CM, alongside the ACC Expert Consensus Decision Pathway and the AHA Scientific Statement on its evolving diagnosis and management, evidence suggests that these recommendations are not being integrated routinely into clinical decision-making. This session will equip pharmacists to recognize ATTR-CM pathophysiology to facilitate timely diagnostic workups. Faculty will outline the expanding treatment landscape, while emphasizing the pharmacist’s pivotal role across the care continuum including navigating specialty pharmacy distribution, managing drug interactions and medication use, treatment adjustment based on relevant laboratory values, and delivering patient-centered counseling.

Target audience: Health-system and specialty pharmacists
Type of activity: Application
Release date: June 25, 2026
Expiration date: June 25, 2027
Learner level: Foundational, Intermediate
Time to complete activity: 1.5 hours
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Investigate the clinical burden of transthyretin amyloidosis cardiomyopathy (ATTR-CM) and screening protocols to prevent misdiagnosis
• Examine the guideline recommendations and evidence supporting the use of emerging and novel therapies for ATTR-CM to inform formulary decisions and patient access strategies
• Express multidisciplinary efforts that increase awareness of ATTR-CM and enable appropriate and early patient identification
• Apply data-driven, value-based care strategies to optimize access to ATTR-CM therapies

Accreditation

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-26-185-H01-P. The activity is available for CE credit through June 25, 2027.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Faculty

The following contributors have no relevant financial relationships with ineligible companies to disclose:

Craig J. Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPS, CACP

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Rose Buszka, PharmD, BCPS, CHCP; Kylie Ferrentino; Brianna Winters; and Chloe Taccetta.

Any relevant financial relationships listed for these individuals have been mitigated.

At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with ineligible companies to disclose.

Educational Disclaimer

Continuing professional education activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved by the labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
ceinfo@pharmacytimes.com

Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms